BMYCelgeneFinished
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 386 (final count)
- Started
- Apr 16, 2019
- Main results expected
- Apr 13, 2026
- Fully finished
- Apr 13, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: Minimum of 5 years from randomization
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03651128 · record last updated 2026-06-22 · checked 2026-11-09 15:47 UTC